EUVIMEDEUVIMED entdecken
Crossref

Predictive factors for biochemical relapse in non-metastatic prostate cancer following primary radiotherapy

Amila Kovčić iD, Šefika Umihanić, Hasan Osmić, Almedina Muhić, Enida Trumić, Eldar Hamzić, Emir Bećirović, Semir Hadžić, Amir Bećirović, Minela Bećirović, Emir Begagić

Medicinski Glasnik · 2025

DOI: 10.17392/1796-22-01 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medicinski Glasnik, 2025. Verfasst von Amila Kovčić und 10 weiteren Autor:innen. Beteiligte Einrichtung: Clinic of Oncology and Radiotherapy, University Clinical Centre Tuzla, Bosnia and Herzegovina.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

<p><strong>Aim</strong> To investigate the predictors of biochemical relapse (BCR) among patients with non-metastatic prostate cancer treated with radiotherapy as the first-line therapy.&nbsp;<br /><strong>Methods</strong> The study included 91 patients diagnosed with prostate cancer at the University Clinical Centre in Tuzla, Bosnia and Herzegovina. After the radiation treatment as the first line of treatment, the patients were monitored for the next 36 months. If patients were classified in medium and high-risk groups, hormone therapy was administered. The occurrence of BCR was determined based on prostate-specific antigen (PSA) values. Potential prognostic parameters, including Gleason score (GS), PSA, tumour size (TNM), and standardised risk classification (RC), were monitored.<br /><strong>Results</strong> A total of 46 (50.5%) patients were aged 66-75, with a median PSA of 14.50 ng/mL. A Gleason score &lt;6 was found in 72 (79.1%) of patients, and 31 (34.1%) had T2c tumours. The BCR occurred in 32 (35.2%) patients, with a median relapse time of 18 months. Significant predictors of BCR were Gleason score &ge;6 (OR:4.46; p=0.006) and tumour stage &gt;T2b (OR:3.59; p=0.021). The RC showed an Area Under Curve (AUC) of 0.634 (p=0.050), indicating its potential diagnostic accuracy.<br /><strong>Conclusion</strong> Gleason score &ge;6 and TNM&gt;T2b are significant predictors of biochemical relapse in prostate cancer patients treated with radiotherapy. These results emphasize the need for additional monitoring and timely treatment of clinical disease progression in patients with Gleason score &ge;6 and tumour stage &gt;T2b.</p>

Schlagwörter

Stichwörter der Autor:innen

androgen antagonistsprostate-specific antigenradiotherapy

Autor:innen und Institutionen

  • Clinic of Oncology and Radiotherapy, University Clinical Centre Tuzla, Bosnia and Herzegovina.
  • Hospital for Lung Diseases and Tuberculosis Travnik, Bosnia and Herzegovina.
  • Clinic of Internal Medicine, University Clinical Centre Tuzla, Bosnia and Herzegovina.
  • Department of Neurosurgery, Cantonal Hospital Zenica, Bosnia and Herzegovina.

ORCID-Profile: Amila Kovčić

Zitieren

APA

Kovčić, A., Umihanić, Š., Osmić, H., Muhić, A., Trumić, E., Hamzić, E., Bećirović, E., Hadžić, S., Bećirović, A., Bećirović, M., & Begagić, E. (2025). Predictive factors for biochemical relapse in non-metastatic prostate cancer following primary radiotherapy. Medicinski Glasnik. https://doi.org/10.17392/1796-22-01

Vancouver

Kovčić A, Umihanić Š, Osmić H, Muhić A, Trumić E, Hamzić E, et al. Predictive factors for biochemical relapse in non-metastatic prostate cancer following primary radiotherapy. Medicinski Glasnik. 2025. doi:10.17392/1796-22-01

BibTeX
@article{Kovi2025,
  author = {Kovčić, Amila and Umihanić, Šefika and Osmić, Hasan and Muhić, Almedina and Trumić, Enida and Hamzić, Eldar and Bećirović, Emir and Hadžić, Semir and Bećirović, Amir and Bećirović, Minela and Begagić, Emir},
  title = {Predictive factors for biochemical relapse in non-metastatic prostate cancer following primary radiotherapy},
  journal = {Medicinski Glasnik},
  year = {2025},
  doi = {10.17392/1796-22-01}
}
Kostenlos starten →